To Evaluate the Safety and Efficacy of GS1191-0445 Injection in the Treatment of Severe Hemophilia A

NCT07548411 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Severe Hemophilia A

Interventions

DRUG: GS1191-0445 injection

Sponsor

Gritgen Therapeutics Co., Ltd.